
  
    
      
        Background_NNP
        The_DT effects_NNS of_IN the_DT vitamin_NN A_DT metabolite_NN retinoic_JJ acid_NN
        (_( RA_NNP )_) are_VBP mediated_JJ by_IN two_CD classes_NNS of_IN ligand_NN dependent_JJ
        transcription_NN factors_NNS ,_, the_DT retinoic_JJ acid_NN receptors_NNS (_( RAR_NNP )_)
        and_CC the_DT retinoid_NN X_NNP receptors_NNS (_( RXR_NNP )_) [_NN 1_CD ]_NN ._. The_DT RARs_NNP are_VBP
        activated_VBN by_IN all_DT trans_NNS RA_NNP and_CC 9_CD -_: cis_NNS RA_NNP whereas_IN the_DT RXRs_NNP are_VBP
        activated_VBN by_IN 9_CD -_: cis_NNS RA_NNP only_RB ._. There_EX are_VBP three_CD known_VBN members_NNS
        of_IN each_DT class_NN (_( termed_VBD α_NN ,_, β_NN ,_, and_CC γ_NN )_) encoded_JJ by_IN separate_JJ
        genes_NNS ._. Each_DT gene_NN may_MD express_VB several_JJ different_JJ isoforms_NNS
        because_IN of_IN alternative_NN splicing_VBG and_CC differential_NN promoter_NN
        usage_NN [_NN 2_CD ]_NN ._. Both_DT the_DT RARs_NNP and_CC RXRs_NNP contain_VBP functional_JJ
        domains_NNS for_IN DNA_NNP and_CC ligand_NN binding_JJ ,_, dimerization_NN with_IN other_JJ
        transcription_NN factors_NNS ,_, and_CC transactivation_NN of_IN RA_NNP responsive_JJ
        promoters_NNS ._. RARs_NNP and_CC RXRs_NNP function_NN as_IN heterodimers_NNS that_WDT bind_NN
        to_TO response_NN elements_NNS in_IN the_DT promoters_NNS of_IN target_NN genes_NNS to_TO
        regulate_VB RA_NNP dependent_JJ transcription_NN ._. RAR_NNP /_NN RXR_NNP binding_JJ to_TO
        nuclear_JJ receptor_NN corepressors_NNS such_JJ as_IN NCoR_NNP and_CC SMRT_NNP in_IN the_DT
        absence_NN of_IN ligand_NN inhibits_NNS activation_NN of_IN RA_NNP responsive_JJ
        genes_NNS [_NN 3_CD 4_CD ]_NN ._. Ligand_NNP binding_VBG displaces_NNS the_DT repressors_NNS and_CC
        recruits_VBZ coactivator_NN proteins_NNS such_JJ as_IN CBP_NNP which_WDT have_VBP
        histone_NN acetyltransferase_NN activity_NN [_NN 5_CD ]_NN ._. Histone_NNP
        acetylation_NN allows_VBZ for_IN chromatin_NN unwinding_VBG and_CC
        transcriptional_NN initiation_NN of_IN target_NN gene_NN expression_NN [_NN 6_CD ]_NN
        ._.
        Previous_JJ studies_NNS have_VBP demonstrated_VBN that_IN
        posttranslational_NN modifications_NNS of_IN RARs_NNP and_CC RXRs_NNP are_VBP
        critical_JJ to_TO the_DT biological_JJ activity_NN of_IN the_DT receptors_NNS ._. In_IN
        the_DT RARα_NNP amino_JJ terminus_JJ ,_, a_DT consensus_NN mitogen_NN activated_VBN
        protein_NN kinase_NN (_( MAPK_NNP )_) phosphorylation_NN sequence_NN was_VBD found_VBN to_TO
        be_VB a_DT target_NN of_IN cyclin_NN H_NNP and_CC cdk_NN 7_CD [_NN 7_CD ]_NN ._. RARα_NNP was_VBD shown_VBN to_TO
        bind_NN the_DT cyclin_NN H_NNP /_NN cdk_NN 7_CD complex_JJ in_IN vitro_NN and_CC phosphorylation_NN
        of_IN serine_NN 77_CD enhanced_VBD the_DT transactivation_NN function_NN of_IN RARα_NNP ._.
        This_DT phosphorylation_NN was_VBD required_VBN for_IN the_DT RA_NNP mediated_JJ
        differentiation_NN of_IN F_NN 9_CD cells_NNS into_IN parietal_NN endoderm_NN [_NN 8_CD ]_NN ._.
        These_DT studies_NNS point_VBP to_TO the_DT importance_NN of_IN phosphorylation_NN in_IN
        the_DT proper_JJ functioning_NN of_IN RARs_NNP ._.
        Mutation_NNP of_IN serine_NN 77_CD to_TO alanine_NN in_IN RARα_NNP has_VBZ been_VBN shown_VBN
        to_TO inhibit_VB the_DT basal_NN activation_NN function_NN of_IN the_DT receptor_NN [_NN
        7_CD ]_NN ._. Other_JJ mutations_NNS have_VBP also_RB been_VBN shown_VBN to_TO decrease_VB RAR_NNP
        function_NN ._. RAC_NNP 65_CD cells_NNS ,_, an_DT RA_NNP resistant_JJ clone_NN of_IN the_DT
        pluripotent_NN P_NN 19_CD embryonal_NN carcinoma_NN line_NN ,_, express_VBP a_DT
        truncated_JJ RARα_NNP that_WDT lacks_VBZ part_NN of_IN the_DT ligand_NN binding_JJ domain_NN
        [_NN 9_CD ]_NN ._. As_IN a_DT result_NN of_IN this_DT mutation_NN ,_, RAC_NNP 65_CD cells_NNS do_VBP not_RB
        differentiate_VB when_WRB exposed_VBN to_TO RA_NNP ._. An_DT RARα_NNP clone_NN truncated_JJ
        after_IN amino_JJ acid_NN 403_CD was_VBD effective_JJ in_IN repressing_VBG reporter_NN
        gene_NN activity_NN and_CC blocking_VBG wild_JJ type_NN RAR_NNP function_NN [_NN 10_CD 11_CD ]_NN
        ._. A_DT single_JJ amino_JJ acid_NN change_NN in_IN RARα_NNP (_( G_NNP 303_CD E_NNP )_) impaired_VBN RA_NNP
        binding_JJ affinity_NN and_CC significantly_RB reduced_VBN reporter_NN gene_NN
        activity_NN from_IN responsive_JJ promoters_NNS ._. These_DT studies_NNS
        illustrate_VBP the_DT usefulness_NN of_IN dominant_JJ negative_JJ RAR_NNP mutants_NNS
        in_IN elucidating_VBG mechanisms_NNS of_IN RA_NNP signaling_VBG ._.
        In_IN the_DT present_JJ study_NN we_PRP show_VBP that_IN RA_NNP ,_, by_IN inhibiting_VBG
        cyclin_NN H_NNP and_CC cdk_NN 7_CD expression_NN ,_, reduces_VBZ phosphorylation_NN of_IN
        RARα_NNP ._. We_PRP examined_VBD the_DT role_NN of_IN hypophosphorylated_JJ RARα_NNP by_IN
        mutating_VBG the_DT cdk_NN 7_CD phosphorylation_NN site_NN in_IN the_DT receptor_NN
        amino_JJ terminus_JJ (_( S_NNP 77_CD A_DT )_) ._. The_DT S_NNP 77_CD A_DT RARα_NNP mutant_JJ decreased_VBD
        proliferation_NN of_IN human_JJ cancer_NN cells_NNS consistent_JJ with_IN
        inhibition_NN of_IN the_DT G_NNP 1_CD /_NN S_NNP phase_NN transition_NN ._. Decreased_NNP
        proliferation_NN of_IN the_DT mutant_JJ clones_NNS was_VBD associated_VBN with_IN
        inhibition_NN of_IN EGFR_NNP mediated_JJ AP-_NNP 1_CD expression_NN and_CC ERK_NNP 1_CD
        activity_NN ,_, similar_JJ to_TO the_DT effects_NNS of_IN RA_NNP ._. This_DT study_NN
        illustrates_VBZ a_DT novel_NN mechanism_NN by_IN which_WDT RA_NNP inhibits_NNS
        proliferation_NN (_( i_NNP ._. e_SYM ._. ,_, by_IN decreasing_VBG RARα_NNP phosphorylation_NN )_)
        and_CC that_IN in_IN the_DT absence_NN of_IN ligand_NN ,_, hypophosphorylated_JJ RARα_NNP
        can_MD mimic_VB the_DT molecular_JJ and_CC cellular_JJ changes_NNS associated_VBN
        with_IN retinoid_NN treatment_NN ._.
      
      
        Results_NNS
        The_DT mechanisms_NNS which_WDT regulate_VB cyclin_NN H_NNP /_NN cdk_NN 7_CD
        phosphorylation_NN of_IN RARα_NNP have_VBP not_RB been_VBN elucidated_JJ ._. To_TO
        determine_VB if_IN RA_NNP itself_PRP could_MD affect_VB the_DT phosphorylation_NN
        status_NN of_IN its_PRP$ receptor_NN ,_, we_PRP treated_VBD SCC_NNP 4_CD and_CC SCC_NNP 25_CD lines_NNS
        with_IN 1_CD μM_NN all_DT trans_NNS RA_NNP for_IN 16_CD hours_NNS ._. As_IN shown_VBN in_IN Fig_NNP ._. 1_LS A_DT ,_,
        RA_NNP treatment_NN decreased_VBD expression_NN of_IN both_DT cyclin_NN H_NNP and_CC cdk_NN 7_CD
        in_IN SCC_NNP 4_CD and_CC SCC_NNP 25_CD cells_NNS by_IN 3_CD fold_VB ._. To_TO determine_VB if_IN reduced_VBN
        cyclin_NN H_NNP and_CC cdk_NN 7_CD expression_NN correlated_JJ with_IN decreased_VBD RARα_NNP
        phosphorylation_NN ,_, we_PRP immunoprecipitated_JJ the_DT receptor_NN from_IN
        vehicle_NN and_CC RA_NNP treated_VBD SCC_NNP 4_CD and_CC SCC_NNP 25_CD cells_NNS ._. As_IN shown_VBN in_IN
        Fig_NNP ._. 1_LS B_NNP ,_, relative_JJ phosphorylation_NN levels_NNS of_IN RARα_NNP decreased_VBN
        by_IN 3_CD fold_VB ,_, similar_JJ to_TO the_DT reduction_NN in_IN cyclin_NN H_NNP and_CC cdk_NN 7_CD
        expression_NN ._. Previous_JJ studies_NNS have_VBP shown_VBN that_IN the_DT amino_JJ
        terminus_JJ of_IN the_DT estrogen_NN receptor_NN is_VBZ phosphorylated_JJ by_IN MAPK_NNP
        proteins_NNS [_NN 12_CD ]_NN ._. To_TO determine_VB the_DT participation_NN of_IN MAPKs_NNP
        in_IN RARα_NNP phosphorylation_NN ,_, we_PRP performed_VBD RARα_NNP
        immunoprecipitation_NN on_IN SCC_NNP 25_CD cells_NNS treated_VBN with_IN the_DT MEK_NNP /_NN ERK_NNP
        inhibitor_NN PD_NNP 98059_CD or_CC p_NN 38_CD inhibitory_NN drug_NN SB_NNP 203580_CD ._.
        Treatment_NNP with_IN these_DT drugs_NNS did_VBD not_RB change_VB relative_JJ RARα_NNP
        phosphorylation_NN levels_NNS (_( Fig_NNP ._. 1_LS B_NNP )_) ._. We_PRP concluded_VBD that_IN RA_NNP
        repressed_JJ cyclin_NN H_NNP /_NN cdk_NN 7_CD expression_NN which_WDT correlated_JJ with_IN
        reduced_VBN RARα_NNP phosphorylation_NN levels_NNS ._.
        RA_NNP is_VBZ a_DT potent_JJ inhibitor_NN of_IN cellular_JJ proliferation_NN [_NN 13_CD
        ]_NN ._. To_TO determine_VB the_DT effects_NNS of_IN hypophosphorylated_JJ RARα_NNP on_IN
        the_DT growth_NN of_IN human_JJ cancer_NN cells_NNS ,_, we_PRP expressed_VBD an_DT S_NNP 77_CD A_DT RARα_NNP
        expression_NN construct_VB in_IN SCC_NNP 25_CD cells_NNS ._. The_DT serine_NN residue_NN at_IN
        position_NN 77_CD was_VBD previously_RB shown_VBN to_TO be_VB the_DT target_NN of_IN cyclin_NN
        H_NNP /_NN cdk_NN 7_CD phosphorylation_NN [_NN 7_CD ]_NN ._. As_IN shown_VBN in_IN Fig_NNP ._. 2_LS ,_,
        expression_NN of_IN the_DT S_NNP 77_CD A_DT mutant_JJ resulted_VBD in_IN decreased_VBD
        relative_JJ phosphorylation_NN of_IN immunoprecipitated_JJ RARα_NNP in_IN
        stable_JJ clones_NNS compared_VBN to_TO G_NNP 418_CD resistant_JJ control_NN cells_NNS ._. To_TO
        confirm_VB that_IN this_DT effect_NN was_VBD due_JJ to_TO expression_NN of_IN the_DT
        hypophosphorylated_JJ RARα_NNP mutant_JJ ,_, we_PRP also_RB created_VBD stable_JJ
        clones_NNS expressing_VBG either_CC HA_NNP tagged_VBN RARα_NNP or_CC the_DT S_NNP 77_CD A_DT mutant_JJ ._.
        As_IN shown_VBN in_IN Fig_NNP ._. 3_LS ,_, only_RB clones_NNS expressing_VBG HA-RARα_NNP and_CC not_RB
        the_DT HA-S_NNP 77_CD A_DT mutant_JJ showed_VBD phosphorylation_NN on_IN serine_NN
        residues_NNS ._. These_DT experiments_NNS indicate_VBP that_IN the_DT relative_JJ
        amount_NN of_IN phosphorylated_JJ RARα_NNP in_IN SCC_NNP 25_CD cells_NNS was_VBD decreased_VBN
        by_IN the_DT S_NNP 77_CD A_DT mutant_JJ ._. SCC_NNP 25_CD cells_NNS expressing_VBG the_DT S_NNP 77_CD A_DT mutant_JJ
        RARα_NNP proliferated_VBN at_IN markedly_RB reduced_VBN rates_NNS compared_VBN to_TO
        control_VB clones_NNS (_( Fig_NNP ._. 4_LS )_) ._. The_DT S_NNP 77_CD A_DT RARα_NNP mutants_NNS grew_VBD at_IN only_RB
        30_CD -_: 50_CD %_NN of_IN the_DT rate_NN of_IN G_NNP 418_CD resistant_JJ controls_NNS in_IN culture_NN ._.
        By_IN comparison_NN ,_, proliferation_NN of_IN clones_NNS expressing_VBG HA_NNP tagged_VBN
        RARα_NNP was_VBD 90_CD %_NN of_IN G_NNP 418_CD resistant_JJ control_NN cells_NNS ._. We_PRP concluded_VBD
        that_WDT decreased_VBD RARα_NNP phosphorylation_NN produces_VBZ inhibition_NN of_IN
        proliferation_NN in_IN SCC_NNP 25_CD cells_NNS ._.
        To_TO determine_VB if_IN decreased_VBD proliferation_NN of_IN the_DT mutant_JJ
        RARα_NNP clones_NNS correlated_JJ with_IN inhibition_NN of_IN cell_NN cycle_NN
        progression_NN ,_, we_PRP performed_VBD BrdU_NNP incorporation_NN analysis_NN ._. As_IN
        shown_VBN in_IN Fig_NNP ._. 5_LS ,_, less_JJR than_IN half_PDT the_DT percentage_NN of_IN S_NNP 77_CD A_DT
        mutant_JJ cells_NNS incorporated_VBD BrdU_NNP compared_VBD to_TO the_DT G_NNP 418_CD
        resistant_JJ control_NN clones_NNS ._. By_IN comparison_NN ,_, there_EX were_VBD no_DT
        significant_JJ differences_NNS in_IN BrdU_NNP incorporation_NN between_IN HA_NNP
        tagged_VBN RARα_NNP clones_NNS and_CC G_NNP 418_CD resistant_JJ control_NN cells_NNS ._. These_DT
        results_NNS indicate_VBP that_IN the_DT G_NNP 1_CD to_TO S_NNP phase_NN transition_NN of_IN the_DT
        cell_NN cycle_NN is_VBZ inhibited_VBD in_IN S_NNP 77_CD A_DT mutant_JJ clones_NNS ._. To_TO
        corroborate_VBP this_DT conclusion_NN ,_, we_PRP examined_VBD expression_NN of_IN the_DT
        G_NNP 1_CD phase_NN cyclin_NN dependent_JJ kinase_NN inhibitors_NNS p_NN 21_CD
        WAF_NNP 1_CD /_NN Cip_NNP 1_CD and_CC p_NN 27_CD Kip_NNP 1_CD in_IN G_NNP 418_CD resistant_JJ and_CC S_NNP 77_CD A_DT mutant_JJ
        clones_NNS ._. We_PRP also_RB determined_VBD the_DT expression_NN of_IN the_DT S_NNP phase_NN
        marker_NN cyclin_NN A_DT in_IN these_DT cells_NNS ._. As_IN shown_VBN in_IN Fig_NNP ._. 6_CD ,_,
        expression_NN of_IN the_DT G_NNP 1_CD phase_NN markers_NNS p_NN 21_CD WAF_NNP 1_CD /_NN Cip_NNP 1_CD and_CC p_NN 27_CD
        Kip_NNP 1_CD in_IN the_DT mutant_JJ RARα_NNP clones_NNS was_VBD up_IN to_TO 3_CD fold_VB higher_JJR
        compared_VBN to_TO control_VB cells_NNS ._. In_IN contrast_NN ,_, expression_NN of_IN the_DT S_NNP
        phase_NN marker_NN cyclin_NN A_DT was_VBD decreased_VBN by_IN 3_CD fold_VB in_IN two_CD clones_NNS
        (_( RAR_NNP 1_CD and_CC 2_LS )_) and_CC was_VBD undetectable_JJ in_IN 2_CD others_NNS (_( RAR_NNP 3_CD and_CC 4_LS )_)
        when_WRB compared_VBN to_TO G_NNP 418_CD resistant_JJ control_NN cells_NNS ._. These_DT
        results_NNS indicate_VBP that_IN the_DT decreased_VBN proliferation_NN observed_VBD
        in_IN S_NNP 77_CD A_DT RARα_NNP mutant_JJ clones_NNS is_VBZ due_JJ to_TO inhibition_NN of_IN cell_NN
        cycle_NN progression_NN at_IN the_DT G_NNP 1_CD to_TO S_NNP phase_NN transition_NN ._.
        The_DT antiproliferative_JJ effects_NNS of_IN RA_NNP have_VBP been_VBN attributed_VBN
        to_TO its_PRP$ inhibition_NN of_IN AP-_NNP 1_CD transcriptional_NN activity_NN [_NN 13_CD ]_NN ._.
        While_IN the_DT S_NNP 77_CD A_DT RARα_NNP mutant_JJ has_VBZ been_VBN shown_VBN to_TO inhibit_VB
        transactivation_NN of_IN RA_NNP response_NN elements_NNS [_NN 7_CD ]_NN ,_, its_PRP$ effects_NNS
        on_IN AP-_NNP 1_CD activity_NN have_VBP not_RB been_VBN characterized_VBN ._. We_PRP first_RB
        addressed_VBD this_DT issue_NN by_IN transiently_RB transfecting_VBG a_DT
        heterologous_JJ promoter_NN containing_VBG a_DT consensus_NN AP-_NNP 1_CD site_NN
        fused_JJ to_TO the_DT luciferase_NN reporter_NN gene_NN [_NN 11_CD ]_NN along_IN with_IN
        wild_JJ type_NN RARα_NNP or_CC S_NNP 77_CD A_DT mutant_JJ expression_NN vectors_NNS ._. In_IN the_DT
        absence_NN of_IN ligand_NN ,_, the_DT S_NNP 77_CD A_DT RARα_NNP mutant_JJ inhibited_VBD AP-_NNP 1_CD
        activity_NN from_IN this_DT construct_VB by_IN 50_CD %_NN ,_, similar_JJ to_TO treatment_NN
        with_IN 1_CD μM_NN all_DT trans_NNS RA_NNP (_( Fig_NNP ._. 7_CD )_) ._. The_DT wild_JJ type_NN receptor_NN
        possessed_VBD slight_JJ anti-_NN AP-_NNP 1_CD activity_NN in_IN the_DT absence_NN of_IN
        ligand_NN (_( 20_CD %_NN reduction_NN compared_VBN to_TO control_VB cells_NNS transfected_JJ
        with_IN blank_JJ expression_NN vector_NN )_) ._. These_DT results_NNS indicate_VBP that_IN
        hypophosphorylated_JJ RARα_NNP can_MD mimic_VB the_DT effects_NNS of_IN RA_NNP by_IN
        inhibiting_VBG AP-_NNP 1_CD activity_NN ._.
        To_TO determine_VB if_IN reductions_NNS in_IN AP-_NNP 1_CD protein_NN levels_NNS could_MD
        account_VB for_IN the_DT observed_VBN transcriptional_NN inhibition_NN by_IN the_DT
        S_NNP 77_CD A_DT mutant_JJ RARα_NNP ,_, we_PRP compared_VBD expression_NN of_IN fos_NNS and_CC jun_NN
        proteins_NNS in_IN G_NNP 418_CD resistant_JJ control_NN clones_NNS and_CC S_NNP 77_CD A_DT RARα_NNP
        expressing_VBG cells_NNS ._. As_IN shown_VBN in_IN Fig_NNP ._. 8_CD ,_, Fra-_NNP 1_CD expression_NN was_VBD
        undetectable_JJ in_IN 3_CD of_IN 4_CD RARα_NNP mutant_JJ clones_NNS ._. Expression_NNP of_IN
        c-jun_JJ was_VBD reduced_VBN by_IN 3_CD to_TO 4_CD fold_VB in_IN the_DT S_NNP 77_CD A_DT RARα_NNP cells_NNS
        compared_VBN to_TO G_NNP 418_CD resistant_JJ control_NN clones_NNS ._. JunB_NNP expression_NN
        was_VBD also_RB decreased_VBN by_IN up_IN to_TO 20_CD fold_VB in_IN mutant_JJ RARα_NNP
        expressing_VBG cells_NNS ._. Expression_NNP of_IN c-fos_JJ ,_, Fra-_NNP 2_CD ,_, FosB_NNP ,_, and_CC
        JunD_NNP was_VBD not_RB detected_VBN under_IN normal_JJ growth_NN conditions_NNS in_IN
        SCC_NNP 25_CD cells_NNS ._. These_DT results_NNS indicate_VBP that_WDT decreased_VBN AP-_NNP 1_CD
        protein_NN expression_NN correlates_NNS with_IN AP-_NNP 1_CD transcriptional_NN
        inhibition_NN by_IN hypophosphorylated_JJ RARα_NNP ._.
        Upstream_NNP of_IN AP-_NNP 1_CD transcription_NN factors_NNS ,_, RA_NNP has_VBZ been_VBN
        shown_VBN to_TO inhibit_VB epidermal_NN growth_NN factor_NN receptor_NN (_( EGFR_NNP )_)
        expression_NN [_NN 14_CD ]_NN ._. To_TO determine_VB if_IN hypophosphorylated_JJ RARα_NNP
        could_MD inhibit_VB EGFR_NNP expression_NN ,_, we_PRP examined_VBD expression_NN of_IN
        the_DT growth_NN factor_NN receptor_NN by_IN western_JJ blot_NN in_IN control_NN and_CC
        S_NNP 77_CD A_DT mutant_JJ cells_NNS ._. As_IN shown_VBN in_IN Fig_NNP ._. 9_CD ,_, EGFR_NNP expression_NN was_VBD
        undetectable_JJ in_IN 3_CD of_IN 4_CD mutant_JJ RARα_NNP clones_NNS and_CC was_VBD reduced_VBN
        by_IN 50_CD %_NN in_IN the_DT remaining_VBG clone_NN (_( RAR_NNP 1_LS )_) ._. To_TO determine_VB if_IN this_DT
        dramatically_RB decreased_VBN EGFR_NNP expression_NN could_MD inhibit_VB
        downstream_JJ components_NNS of_IN EGF_NNP signaling_VBG ,_, we_PRP also_RB examined_VBD
        activation_NN of_IN ERK_NNP 1_CD (_( a_DT terminal_NN effector_NN in_IN the_DT mitogen_NN
        activated_VBN protein_NN kinase_NN pathway_NN )_) ._. Activated_NNP ERK_NNP 1_CD in_IN S_NNP 77_CD A_DT
        mutant_JJ cells_NNS was_VBD expressed_VBN at_IN less_JJR than_IN 10_CD %_NN of_IN the_DT levels_NNS
        found_VBD in_IN G_NNP 418_CD resistant_JJ control_NN clones_NNS ._. Overall_RB ERK_NNP 1_CD
        expression_NN was_VBD not_RB affected_VBN by_IN hypophosphorylated_JJ RARα_NNP ._.
        These_DT results_NNS indicate_VBP that_IN components_NNS of_IN the_DT EGFR_NNP
        signaling_VBG pathway_NN ,_, upstream_RB of_IN AP-_NNP 1_CD transcription_NN factors_NNS ,_,
        are_VBP inhibited_VBD by_IN hypophosphorylated_JJ RARα_NNP ._.
        Activation_NNP of_IN growth_NN factor_NN receptors_NNS has_VBZ been_VBN shown_VBN to_TO
        induce_VB expression_NN of_IN AP-_NNP 1_CD proteins_NNS [_NN 15_CD ]_NN ._. To_TO determine_VB if_IN
        EGF_NNP signaling_VBG correlated_JJ with_IN AP-_NNP 1_CD activity_NN in_IN SCC_NNP 25_CD cells_NNS ,_,
        we_PRP first_JJ incubated_JJ cultures_NNS in_IN 1_CD %_NN depleted_VBD serum_NN for_IN 16_CD
        hours_NNS to_TO inhibit_VB AP-_NNP 1_CD protein_NN expression_NN ._. We_PRP then_RB
        stimulated_VBN these_DT cultures_NNS with_IN 10_CD ng_NN /_NN ml_NN EGF_NNP for_IN up_IN to_TO 4_CD
        hours_NNS ._. As_IN shown_VBN in_IN Fig_NNP ._. 10_CD ,_, EGF_NNP produced_VBD dramatic_JJ induction_NN
        of_IN AP-_NNP 1_CD protein_NN expression_NN within_IN 15_CD minutes_NNS after_IN its_PRP$
        addition_NN ._. c-fos_JJ expression_NN peaked_VBD at_IN 100_CD fold_VB over_IN
        unstimulated_JJ levels_NNS at_IN 2_CD hours_NNS following_VBG EGF_NNP addition_NN ._.
        Following_VBG a_DT similar_JJ time_NN course_NN ,_, c-jun_JJ expression_NN increased_VBD
        by_IN 25_CD fold_VB following_VBG stimulation_NN by_IN EGF_NNP ._. Induction_NNP of_IN Fra-_NNP 1_CD
        and_CC JunB_NNP expression_NN was_VBD also_RB noted_VBN ,_, although_IN the_DT increase_NN
        was_VBD of_IN less_JJR magnitude_NN than_IN that_DT observed_VBD for_IN c-fos_JJ and_CC
        c-jun_JJ ._. The_DT effects_NNS of_IN EGF_NNP on_IN AP-_NNP 1_CD protein_NN expression_NN were_VBD
        completely_RB blocked_VBN by_IN the_DT EGFR_NNP kinase_NN inhibitor_NN tyrphostin_NN
        AG_NNP 1478_CD (_( data_NNS not_RB shown_VBN )_) ,_, indicating_VBG that_DT growth_NN factor_NN
        receptor_NN signaling_VBG directly_RB correlates_NNS with_IN AP-_NNP 1_CD protein_NN
        expression_NN ._. These_DT data_NNS suggest_VBP that_IN in_IN the_DT unliganded_JJ
        state_NN ,_, hypophosphorylated_JJ RARα_NNP can_MD mimic_VB the_DT effects_NNS of_IN RA_NNP
        on_IN EGFR_NNP expression_NN ,_, ERK_NNP 1_CD activity_NN ,_, and_CC AP-_NNP 1_CD protein_NN
        levels_NNS ._.
      
      
        Conclusions_NNP
        The_DT antiproliferative_JJ effects_NNS of_IN RA_NNP have_VBP been_VBN recognized_VBN
        for_IN many_JJ years_NNS ._. This_DT important_JJ chemotherapeutic_JJ property_NN of_IN
        RA_NNP has_VBZ been_VBN attributed_VBN to_TO a_DT number_NN of_IN molecular_JJ mechanisms_NNS ._.
        Decreased_NNP growth_NN factor_NN and_CC growth_NN factor_NN receptor_NN
        expression_NN has_VBZ been_VBN proposed_VBN as_IN a_DT potential_JJ growth_NN
        inhibitory_NN mechanism_NN [_NN 14_CD ]_NN ._. Additionally_RB ,_, RA_NNP mediated_JJ
        inhibition_NN of_IN AP-_NNP 1_CD activity_NN is_VBZ believed_VBN to_TO be_VB important_JJ in_IN
        cellular_JJ growth_NN control_NN by_IN this_DT ligand_NN [_NN 13_CD ]_NN ._. AP-_NNP 1_CD
        inhibition_NN via_IN direct_JJ interaction_NN between_IN RARs_NNP and_CC AP-_NNP 1_CD
        proteins_NNS has_VBZ been_VBN proposed_VBN [_NN 16_CD ]_NN ._. RA_NNP inhibition_NN of_IN jun_NN
        N-_NNP terminal_NN kinase_NN was_VBD shown_VBN to_TO prevent_VB c-jun_JJ
        phosphorylation_NN ,_, resulting_VBG in_IN decreased_VBD AP-_NNP 1_CD activity_NN [_NN 17_CD
        ]_NN ._. Competition_NN between_IN RAR_NNP and_CC AP-_NNP 1_CD for_IN limiting_VBG amounts_NNS
        of_IN the_DT nuclear_JJ receptor_NN coactivator_NN CBP_NNP may_MD also_RB account_VB
        for_IN decreases_NNS in_IN AP-_NNP 1_CD transcriptional_NN activity_NN [_NN 5_CD ]_NN ._. In_IN
        the_DT present_JJ study_NN we_PRP have_VBP described_VBN a_DT new_JJ mechanism_NN by_IN
        which_WDT RA_NNP can_MD inhibit_VB cellular_JJ proliferation_NN ._. RA_NNP inhibited_VBD
        cyclin_NN H_NNP and_CC cdk_NN 7_CD expression_NN which_WDT correlated_JJ with_IN
        hypophosphorylation_NN of_IN RARα_NNP on_IN serine_NN 77_CD ._. To_TO separate_VB the_DT
        specific_JJ role_NN of_IN hypophosphorylated_JJ RARα_NNP from_IN the_DT
        pleiotropic_JJ effects_NNS of_IN the_DT ligand_NN ,_, we_PRP expressed_VBD a_DT
        non-phosphorylatable_JJ S_NNP 77_CD A_DT mutant_JJ protein_NN in_IN human_JJ cancer_NN
        cells_NNS ._. The_DT S_NNP 77_CD A_DT RARα_NNP mutant_JJ inhibited_VBD proliferation_NN of_IN
        SCC_NNP 25_CD cells_NNS even_RB in_IN the_DT absence_NN of_IN RA_NNP ,_, thereby_RB mimicking_VBG
        the_DT growth_NN inhibitory_NN effect_NN of_IN the_DT ligand_NN ._. This_DT growth_NN
        inhibition_NN correlated_JJ with_IN a_DT delay_NN in_IN G_NNP 1_CD to_TO S_NNP phase_NN
        progression_NN ._. EGFR_NNP expression_NN ,_, ERK_NNP 1_CD activation_NN ,_, and_CC AP-_NNP 1_CD
        activity_NN were_VBD inhibited_VBD by_IN the_DT mutant_JJ RAR_NNP ,_, effects_VBZ which_WDT
        are_VBP also_RB achieved_VBN by_IN RA_NNP treatment_NN alone_RB ._. We_PRP determined_VBD that_IN
        decreases_NNS in_IN AP-_NNP 1_CD protein_NN expression_NN observed_VBD in_IN the_DT RARα_NNP
        mutant_JJ clones_NNS were_VBD primarily_RB due_JJ to_TO diminished_VBN EGFR_NNP
        signaling_VBG ._. Therefore_RB while_IN ligand_NN bound_VBN RARα_NNP has_VBZ been_VBN shown_VBN
        to_TO activate_VBP a_DT large_JJ number_NN of_IN RA_NNP target_NN genes_NNS ,_, the_DT
        hypophosphorylated_JJ form_NN of_IN the_DT receptor_NN created_VBN in_IN some_DT
        cells_NNS following_VBG retinoid_NN treatment_NN may_MD be_VB important_JJ in_IN
        transcriptional_NN repression_NN ._. In_IN support_NN of_IN this_DT hypothesis_NNS ,_,
        Rochette-_NNP Egly_NNP et_CC al_NN ._. [_NN 7_CD ]_NN described_VBD decreased_VBN
        transactivation_NN function_NN by_IN the_DT S_NNP 77_CD A_DT mutant_JJ RARα_NNP ._.
        Previously_RB we_PRP characterized_VBD another_DT RARα_NNP mutant_JJ in_IN which_WDT
        the_DT receptor_NN protein_NN was_VBD truncated_JJ after_IN amino_JJ acid_NN 403_CD ,_,
        thereby_RB deleting_VBG the_DT AF-_NNP 2_CD domain_NN [_NN 11_CD ]_NN ._. This_DT truncated_JJ
        receptor_NN exhibited_VBN similar_JJ properties_NNS to_TO the_DT S_NNP 77_CD A_DT mutant_JJ
        (_( growth_NN inhibition_NN and_CC repression_NN of_IN RA_NNP responsive_JJ gene_NN
        expression_NN including_VBG EGFR_NNP )_) ._. Repression_NN of_IN RA_NNP responsive_JJ
        gene_NN expression_NN was_VBD believed_VBN due_JJ to_TO the_DT inability_NN of_IN this_DT
        RAR_NNP to_TO interact_NN with_IN CBP_NNP via_IN its_PRP$ shortened_VBN carboxyl_NN
        terminus_JJ [_NN 5_CD ]_NN ._. By_IN the_DT same_JJ token_JJ this_DT mutant_JJ receptor_NN did_VBD
        not_RB affect_VB RA_NNP inhibition_NN of_IN AP-_NNP 1_CD activity_NN ,_, presumably_RB due_JJ
        to_TO its_PRP$ inability_NN to_TO compete_VB for_IN CBP_NNP [_NN 11_CD ]_NN ._. We_PRP observed_VBD
        decreased_VBN AP-_NNP 1_CD activity_NN in_IN transient_JJ transfections_NNS using_VBG
        the_DT RAR_NNP 403_CD mutant_JJ likely_JJ due_NN to_TO decreased_VBD EGFR_NNP expression_NN ._.
        However_RB ,_, the_DT mechanisms_NNS by_IN which_WDT the_DT S_NNP 77_CD A_DT mutant_JJ inhibits_NNS
        RA_NNP responsive_JJ gene_NN expression_NN is_VBZ unknown_JJ ._. The_DT RARα_NNP amino_JJ
        terminus_JJ is_VBZ not_RB known_VBN to_TO interact_NN with_IN CBP_NNP or_CC its_PRP$
        associated_VBN factor_NN PCAF_NNP [_NN 5_CD 18_CD ]_NN ._. Additionally_RB ,_, RARs_NNP bind_NN
        to_TO the_DT interaction_NN domains_NNS of_IN repressor_NN proteins_NNS such_JJ as_IN
        NCoR_NNP via_IN region_NN D_NNP of_IN the_DT receptor_NN rather_RB than_IN the_DT amino_JJ
        terminus_JJ [_NN 4_CD ]_NN ._. Despite_IN the_DT lack_NN of_IN obvious_JJ interaction_NN of_IN
        the_DT RAR_NNP amino_JJ terminus_JJ with_IN nuclear_JJ receptor_NN cofactors_NNS ,_, the_DT
        S_NNP 77_CD A_DT mutation_NN may_MD alter_VB the_DT three_CD dimensional_NN structure_NN of_IN
        the_DT receptor_NN ._. This_DT altered_VBN configuration_NN may_MD prevent_VB the_DT
        mutant_JJ receptor_NN from_IN releasing_VBG repressor_NN proteins_NNS or_CC
        recruiting_VBG coactivators_NNS in_IN the_DT presence_NN of_IN ligand_NN ._. The_DT S_NNP 77_CD A_DT
        mutant_JJ receptor_NN was_VBD shown_VBN to_TO inhibit_VB ligand_NN dependent_JJ
        transactivation_NN of_IN RA_NNP responsive_JJ promoters_NNS [_NN 7_CD ]_NN ,_, but_CC the_DT
        mechanism_NN of_IN this_DT reduction_NN (_( e_SYM ._. g_SYM ._. ,_, competition_NN for_IN binding_JJ
        sites_NNS ,_, cofactor_NN interaction_NN ,_, ligand_NN binding_JJ )_) has_VBZ not_RB been_VBN
        determined_VBN ._.
        In_IN summary_NN ,_, decreased_VBD RARα_NNP phosphorylation_NN correlating_VBG
        with_IN RA_NNP mediated_JJ inhibition_NN of_IN cyclin_NN H_NNP and_CC cdk_NN 7_CD expression_NN
        illustrates_VBZ a_DT new_JJ mechanism_NN by_IN which_WDT ligand_NN can_MD indirectly_RB
        regulate_VB receptor_NN activation_NN ._. This_DT raises_VBZ the_DT question_NN of_IN
        how_WRB RA_NNP initially_RB downregulates_NNS cyclin_NN H_NNP and_CC cdk_NN 7_CD
        expression_NN ,_, whether_IN by_IN AP-_NNP 1_CD inhibition_NN or_CC through_IN negative_JJ
        retinoid_NN response_NN elements_NNS in_IN the_DT regulatory_JJ regions_NNS of_IN the_DT
        genes_NNS ._. The_DT characterization_NN of_IN potentially_RB altered_VBN
        interactions_NNS between_IN hypophosphorylated_JJ RARα_NNP and_CC its_PRP$
        cofactors_NNS will_MD provide_VB unique_JJ insight_NN into_IN how_WRB
        post-translational_JJ modification_NN of_IN nuclear_JJ hormone_NN
        receptors_NNS regulates_VBZ repressor_NN release_NN ,_, coactivator_NN
        recruitment_NN ,_, histone_NN acetylation_NN ,_, and_CC transcriptional_NN
        activation_NN ._.
      
      
        Methods_NNP
        
          Cell_NNP culture_NN and_CC stable_JJ transfection_NN
          The_DT human_JJ squamous_JJ cell_NN carcinoma_NN lines_NNS used_VBN in_IN this_DT
          study_NN were_VBD purchased_VBN from_IN the_DT American_NNP Type_NNP Culture_NNP
          Collection_NNP and_CC have_VBP been_VBN described_VBN previously_RB [_NN 11_CD ]_NN ._.
          Cells_NNP were_VBD cultured_JJ in_IN Dulbecco_NNP 's_POS modified_VBN Eagle_NNP medium_NN
          (_( DMEM_NNP )_) ,_, 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) ,_, and_CC 40_CD μg_NN /_NN ml_NN
          gentamicin_NN at_IN 37_CD °_NN C_NNP in_IN a_DT humidified_JJ atmosphere_NN of_IN 5_CD %_NN CO_NNP 
          2_CD ._. S_NNP 77_CD A_DT mutant_JJ or_CC wild_JJ type_NN RARα_NNP
          cDNAs_NNS were_VBD cloned_VBN into_IN the_DT pCruz-HA_JJ expression_NN vector_NN ._.
          These_DT vectors_NNS or_CC blank_JJ plasmid_NN were_VBD transfected_JJ into_IN
          SCC_NNP 25_CD cells_NNS using_VBG Lipofectamine_NNP reagent_NN according_VBG to_TO
          manufacturer_NN 's_POS recommendations_NNS (_( Invitrogen_NNP )_) ._. Cells_NNP were_VBD
          selected_VBN in_IN 400_CD μg_NN /_NN ml_NN G_NNP 418_CD for_IN 14_CD days_NNS ._. Resistant_NNP clones_NNS
          were_VBD picked_VBN for_IN expansion_NN and_CC characterization_NN ._.
        
        
          Western_JJ blot_NN
          SCC_NNP 4_CD and_CC SCC_NNP 25_CD cells_NNS were_VBD treated_VBN with_IN 1_CD μM_NN all_DT trans_NNS
          RA_NNP for_IN 16_CD hours_NNS ._. In_IN a_DT separate_JJ set_NN of_IN experiments_NNS ,_, SCC_NNP 25_CD
          cells_NNS were_VBD cultured_JJ for_IN 16_CD hours_NNS in_IN DMEM_NNP ,_, 1_CD %_NN
          charcoal-resin_JJ treated_VBN FBS_NNP followed_VBN by_IN stimulation_NN with_IN
          10_CD ng_NN /_NN ml_NN epidermal_NN growth_NN factor_NN (_( EGF_NNP )_) for_IN up_IN to_TO 4_CD hours_NNS ._.
          75_CD μg_NN total_JJ cellular_JJ protein_NN was_VBD separated_VBN by_IN SDS-PAGE_NNP on_IN
          10_CD %_NN resolving_VBG gels_NNS under_IN denaturing_VBG and_CC reducing_VBG
          conditions_NNS ._. Protein_NNP lysates_NNS from_IN G_NNP 418_CD resistant_JJ and_CC S_NNP 77_CD A_DT
          mutant_JJ RARα_NNP clones_NNS were_VBD also_RB analyzed_VBN ._. Separated_NNP proteins_NNS
          were_VBD electroblotted_JJ to_TO PVDF_NNP membranes_NNS according_VBG to_TO
          manufacturer_NN 's_POS recommendations_NNS (_( Roche_NNP Molecular_NNP
          Biochemicals_NNP )_) ._. Blots_NNP were_VBD incubated_JJ with_IN antibodies_NNS to_TO
          human_JJ cyclin_NN H_NNP ,_, cdk_NN 7_CD ,_, cyclin_NN A_DT ,_, p_NN 21_CD WAF_NNP 1_CD /_NN Cip_NNP 1_CD ,_, p_NN 27_CD Kip_NNP 1_CD ,_,
          EGFR_NNP ,_, activated_VBN and_CC total_JJ ERK_NNP 1_CD ,_, c-fos_JJ ,_, Fra-_NNP 1_CD ,_, c-jun_JJ ,_,
          JunB_NNP ,_, or_CC β-actin_JJ (_( Santa_NNP Cruz_NNP Biotechnology_NNP )_) for_IN 16_CD hours_NNS
          at_IN 4_CD °_NN C_NNP ._. After_IN washing_VBG in_IN Tris_NNP buffered_JJ saline_NN containing_VBG
          0_CD ._. 1_CD %_NN Tween_NNP 20_CD (_( TBST_NNP ,_, pH_NN 7_CD ._. 4_LS )_) ,_, blots_NNS were_VBD incubated_JJ for_IN 30_CD
          minutes_NNS at_IN room_NN temperature_NN with_IN anti-_NN IgG_NNP secondary_JJ
          antibody_NN conjugated_JJ to_TO horseradish_NN peroxidase_NN ._. Following_VBG
          extensive_JJ washing_NN in_IN TBST_NNP ,_, bands_NNS were_VBD visualized_JJ by_IN the_DT
          enhanced_JJ chemiluminescence_NN method_NN (_( Roche_NNP Molecular_NNP
          Biochemicals_NNP )_) and_CC quantitated_JJ by_IN laser_NN densitometry_NN ._.
        
        
          Immunoprecipitation_NNP
          SCC_NNP 4_CD and_CC SCC_NNP 25_CD cells_NNS were_VBD treated_VBN with_IN 1_CD μM_NN all_DT trans_NNS
          RA_NNP for_IN 16_CD hours_NNS ._. To_TO determine_VB if_IN ERK_NNP 1_CD or_CC p_NN 38_CD MAPKs_NNP
          phosphorylated_JJ RARα_NNP ,_, some_DT cultures_NNS were_VBD treated_VBN with_IN 50_CD
          μM_NN PD_NNP 98059_CD or_CC 10_CD μM_NN SB_NNP 203580_CD for_IN the_DT same_JJ time_NN period_NN ._.
          Cultures_NNP of_IN G_NNP 418_CD resistant_JJ and_CC S_NNP 77_CD A_DT RARα_NNP mutant_JJ clones_NNS
          were_VBD used_VBN in_IN separate_JJ immunoprecipitation_NN experiments_NNS ._.
          Cultures_NNP were_VBD lysed_JJ in_IN 50_CD mM_NN HEPES_NNP (_( pH_NN 7_CD ._. 5_LS )_) ,_, 150_CD mM_NN NaCl_NNP ,_,
          1_CD mM_NN EDTA_NNP ,_, 2_CD ._. 5_CD mM_NN EGTA_NNP ,_, 1_CD mM_NN DTT_NNP ,_, 1_CD %_NN Nonidet_NNP P-_NNP 40_CD ,_, 10_CD %_NN
          glycerol_NN ,_, 1_CD mM_NN NaF_NNP ,_, 0_CD ._. 1_CD mM_NN sodium_NN orthovanadate_NN ,_, and_CC
          protease_NN inhibitors_NNS for_IN 30_CD minutes_NNS at_IN 4_CD °_NN C_NNP ._. Lysates_NNP were_VBD
          centrifuged_JJ at_IN 10_CD ,_, 000_CD ×_NN g_SYM for_IN 10_CD minutes_NNS and_CC anti-_NN RARα_NNP or_CC
          anti-_NN HA_NNP antibodies_NNS (_( Santa_NNP Cruz_NNP Biotechnology_NNP )_) were_VBD
          incubated_JJ with_IN the_DT supernatants_NNS for_IN 1_CD hour_NN at_IN 4_CD °_NN C_NNP ._.
          Antigen-antibody_NNP complexes_NNS are_VBP precipitated_VBD with_IN protein_NN
          A_DT /_NN G_NNP agarose_NN beads_NNS for_IN 1_CD hour_NN at_IN 4_CD °_NN C_NNP ._. Immunoprecipitated_NNP
          proteins_NNS were_VBD washed_VBN three_CD times_NNS with_IN 1_CD ml_NN lysis_NNS buffer_NN ._.
          Samples_NNP were_VBD boiled_VBD in_IN 1_CD ×_NN Laemmli_NNP buffer_NN for_IN 3_CD minutes_NNS ,_,
          separated_VBN by_IN SDS-PAGE_NNP ,_, and_CC blotted_JJ to_TO polyvinylidene_NN
          difluoride_NN membranes_NNS ._. Blots_NNP were_VBD probed_JJ with_IN
          anti-phosphoserine_JJ antibody_NN (_( Zymed_NNP )_) to_TO determine_VB relative_JJ
          phosphorylation_NN levels_NNS of_IN immunoprecipitated_JJ RARα_NNP ._. Blots_NNP
          were_VBD then_RB stripped_VBN and_CC incubated_JJ with_IN anti-_NN RARα_NNP
          antibodies_NNS to_TO ensure_VB equal_JJ amounts_NNS of_IN immunoprecipitated_JJ
          protein_NN in_IN each_DT lane_NN ._. Bands_NNP were_VBD visualized_JJ by_IN the_DT
          enhanced_JJ chemiluminescence_NN method_NN and_CC quantitated_JJ by_IN
          laser_NN densitometry_NN ._.
        
        
          Proliferation_NNP and_CC bromodeoxyuridine_NN incorporation_NN
          analyses_NNS
          5_LS ×_NN 10_CD 4_CD G_NNP 418_CD resistant_JJ SCC_NNP 25_CD control_NN cells_NNS ,_, RARα_NNP
          overexpressing_VBG cells_NNS ,_, or_CC S_NNP 77_CD A_DT mutant_JJ RARα_NNP clones_NNS were_VBD
          plated_JJ in_IN triplicate_NN into_IN 6_CD well_RB tissue_NN culture_NN plates_NNS
          and_CC grown_VBN for_IN 6_CD days_NNS ._. At_IN two_CD day_NN intervals_NNS ,_, cells_NNS were_VBD
          trypsinized_JJ and_CC counted_VBN with_IN a_DT hemacytomter_NN ._. SCC_NNP 25_CD
          control_NN ,_, RARα_NNP overexpressing_VBG ,_, and_CC S_NNP 77_CD A_DT RARα_NNP mutant_JJ clones_NNS
          were_VBD cultured_JJ on_IN plastic_NN then_RB incubated_JJ with_IN 10_CD μM_NN BrdU_NNP
          for_IN 1_CD hour_NN ._. After_IN washing_VBG in_IN PBS_NNP ,_, cells_NNS were_VBD fixed_VBN in_IN 70_CD %_NN
          ethanol_NN ,_, 50_CD mM_NN glycine_NN (_( pH_NN 2_LS )_) for_IN 30_CD minutes_NNS at_IN -_: 20_CD °_NN C_NNP ._.
          Following_VBG extensive_JJ washing_NN in_IN PBS_NNP ,_, cells_NNS were_VBD incubated_JJ
          with_IN mouse_NN anti-_NN BrdU_NNP primary_JJ antibody_NN at_IN 37_CD °_NN C_NNP for_IN 30_CD
          minutes_NNS ._. After_IN washing_VBG in_IN PBS_NNP ,_, cells_NNS were_VBD incubated_JJ with_IN
          anti-mouse_JJ IgG_NNP secondary_JJ antibody_NN conjugated_JJ to_TO
          fluorescein_NN at_IN 37_CD °_NN C_NNP for_IN 30_CD minutes_NNS ._. Following_VBG extensive_JJ
          washing_NN in_IN PBS_NNP ,_, BrdU_NNP positive_JJ cells_NNS were_VBD visualized_JJ by_IN
          fluorescence_NN microscopy_NN ._. The_DT number_NN of_IN positive_JJ cells_NNS was_VBD
          expressed_VBN as_IN a_DT percentage_NN of_IN total_JJ cells_NNS counted_VBN in_IN ten_CD
          randomly_RB selected_VBN high_JJ power_NN fields_NNS ._.
        
        
          Reporter_NNP gene_NN analysis_NN
          Triplicate_NNP dishes_NNS of_IN SCC_NNP 25_CD cells_NNS were_VBD transiently_RB
          transfected_JJ with_IN 5_CD μg_NN luciferase_NN reporter_NN construct_VB
          containing_VBG a_DT heterologous_JJ promoter_NN containing_VBG a_DT consensus_NN
          AP-_NNP 1_CD site_NN 5_CD '_POS -_: TGACTCA-_NNP 3_CD '_POS [_NN 11_CD ]_NN ._. 2_CD μg_NN of_IN wild_JJ type_NN or_CC
          S_NNP 77_CD A_DT mutant_JJ RARα_NNP expression_NN vector_NN was_VBD cotransfected_JJ to_TO
          determine_VB the_DT effects_NNS of_IN RARα_NNP phosphorylation_NN on_IN AP-_NNP 1_CD
          promoter_NN activity_NN ._. 1_LS μg_NN of_IN a_DT β-galactosidase_JJ expression_NN
          vector_NN was_VBD also_RB included_VBN to_TO normalize_VB for_IN transfection_NN
          efficiency_NN ._. Some_DT cultures_NNS were_VBD treated_VBN with_IN 1_CD μM_NN all_DT
          trans_NNS RA_NNP or_CC 0_CD ._. 1_CD %_NN ethanol_NN vehicle_NN for_IN 24_CD hours_NNS ._. Reporter_NNP
          assays_NNS were_VBD performed_VBN using_VBG the_DT Dual-light_NNP kit_NN according_VBG
          to_TO manufacturer_NN 's_POS recommendations_NNS (_( Tropix_NNP )_) ._. Luciferase_NNP
          activity_NN was_VBD normalized_JJ to_TO that_DT of_IN β-galactosidase_JJ for_IN
          each_DT sample_NN ._.
        
      
      
        List_NN of_IN abbreviations_NNS
        AP-_NNP 1_CD ,_, activator_NN protein_NN 1_CD
        BrdU_NNP ,_, bromodeoxyuridine_NN
        CBP_NNP ,_, CREB_NNP binding_JJ protein_NN
        Cdk_NNP ,_, cyclin_NN dependent_JJ kinase_NN
        DMEM_NNP ,_, Dulbecco_NNP 's_POS modified_VBN Eagle_NNP medium_NN
        DTT_NNP ,_, dithiothreitol_NN
        EDTA_NNP ,_, ethylene_NN diammine_NN tetraacetic_JJ acid_NN
        EGF_NNP ,_, epidermal_NN growth_NN factor_NN
        EGFR_NNP ,_, epidermal_NN growth_NN factor_NN receptor_NN
        EGTA_NNP ,_, ethylene_NN glycol-bis_JJ (_( β-aminoethyl_JJ ether_NN )_) N_NNP ,_, N_NNP ,_, N_NNP '_POS ,_,
        N_NNP '_POS tetraacetic_JJ acid_NN
        ERK_NNP 1_CD ,_, extracellular_NN regulated_VBN kinase_NN 1_CD
        FBS_NNP ,_, fetal_JJ bovine_JJ serum_NN
        HA_NNP ,_, hemagglutinin_NN
        HEPES_NNP ,_, hydroxyethylpiperazine_NN ethanesulfonate_NN
        MAPK_NNP ,_, mitogen_NN activated_VBN protein_NN kinase_NN
        NCoR_NNP ,_, nuclear_JJ receptor_NN co-repressor_JJ
        PBS_NNP ,_, phosphate_NN buffered_JJ saline_NN
        PCAF_NNP ,_, p_NN 300_CD /_NN CBP_NNP associated_VBN factor_NN
        RA_NNP ,_, retinoic_JJ acid_NN
        RAR_NNP ,_, retinoic_JJ acid_NN receptor_NN
        RXR_NNP ,_, retinoid_NN X_NNP receptor_NN
        SCC_NNP ,_, squamous_JJ cell_NN carcinoma_NN
        SDS-PAGE_NNP ,_, sodium_NN dodecyl_NN sulfate-polyacrylamide_JJ gel_NN
        electrophoresis_NNS
        SMRT_NNP ,_, silencing_VBG mediator_NN of_IN retinoid_NN and_CC thyroid_NN hormone_NN
        receptors_NNS
        TBST_NNP ,_, Tris_NNP buffered_JJ saline_NN Tween_NNP 20_CD
      
      
        Authors_NNP '_'' contributions_NNS
        DLC_NNP conceived_VBD the_DT study_NN and_CC participated_VBD in_IN its_PRP$ design_NN
        and_CC execution_NN ._. RK_NNP performed_VBD all_DT studies_NNS related_VBN to_TO the_DT
        effects_NNS of_IN RA_NNP on_IN RAR_NNP phosphorylation_NN by_IN cyclin_NN H_NNP /_NN cdk_NN 7_CD ._. Both_DT
        authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
